PYC Therapeutics (ASX:PYC) has announced a pro-rata accelerated non-renounceable entitlement offer to eligible shareholders to raise $146 million.
PYC Therapeutics to raise up to $146 million to support late-stage trials
February 17, 2025 Australian Biotech![](https://e76bb9fd1f54a7a912eb-40f6ec802f763655ee14c32dfe77820e.ssl.cf4.rackcdn.com/d89f65fd8b6907d17cfbbb368abee9c2.jpg)
Latest Video
New Stories
-
Syntara’s topical anti-fibrotic drug leads to significant normalisation of skin in established scars
February 18, 2025 - - Australian Biotech -
Trump suspends law that changed the industry's approach to public affairs
February 18, 2025 - - Latest News -
Pharmx Technologies partners with Toniq to expand pharmacy solutions in New Zealand
February 18, 2025 - - Latest News -
Pfizer teams up with Heart of Australia to expand access to GP education
February 18, 2025 - - Latest News -
HMRI partners with Novartis to supercharge heart health impact
February 17, 2025 - - Latest News -
PYC Therapeutics to raise up to $146 million to support late-stage trials
February 17, 2025 - - Australian Biotech -
Australia isn’t ready for the next cardiac epidemic, warns landmark heart valve disease report
February 17, 2025 - - Latest News